Laboratory Corporation of America Holdings (LH) has an average broker rating of 1.54, which is interpreted as a Buy, as rated by 14 equity analysts. Nonetheless, 9 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.
Laboratory Corporation of America Holdings (LH) : The consensus price target for Laboratory Corporation of America Holdings (LH) is $147.58 for the short term with a standard deviation of $9.3. The most optimist securities analyst among the 13 who monitor the stock believes that the stock can reach $160, however, the pessimist price target for the company is $132.
For the current week, the company shares have a recommendation consensus of Buy. Laboratory Corporation of America Holdings (NYSE:LH): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $140.27 and $140.27 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $141.05. The buying momentum continued till the end and the stock did not give up its gains. It closed at $140.98, notching a gain of 0.59% for the day. The total traded volume was 437,406 . The stock had closed at $140.15 on the previous day.
In a related news,The director officer (President & CEO) of Laboratory Corp Of America Holdings, King David P sold 196,400 shares at $128.42 on June 13, 2016. The Insider selling transaction had a total value worth of $25,221,688. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Companys non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, womens health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.